EGFR and non-small cell lung carcinoma: We suspect that the antiproliferative activities of the new compounds against NSCLC cells probably incompletely depend on the EGFR inhibitory effects, H460 and A549 cells do not express EGFR-activating mutations, and H1975 cells, which are resistant to Erlotinib, whereas are sensitive to some Erlotinib derivatives.